Back to top

MTN-004 was a Phase I study that tested the safety and acceptability of VivaGel® (SPL7013 Gel) in HIV-negative women ages 18 to 24. The study, a collaboration with the NIH’s Adolescent Trials Network (ATN) for HIV/AIDS Interventions, was conducted at two U.S. sites and one in Puerto Rico. Results, reported in May 2010, found VivaGel was generally well-tolerated but less acceptable to use than the two placebo gels studied.


Phase I Study Finds Candidate Microbicide VivaGel Generally Well Tolerated but Women Less Willing to Use It



MTN-004 Backgrounder



MTN-004 Q&A



See Also

MTN-004 Study Protocol


MTN-004 Study Page


Safety of new microbicide for HIV prevention to be tested in young women in U.S. trial